Elanco Animal Health Incorporated (NYSE:ELAN) Receives $16.43 Average Target Price from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have received an average recommendation of "Hold" from the eight analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $16.43.

Several research firms have recently weighed in on ELAN. Morgan Stanley lowered Elanco Animal Health from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, November 8th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a "market perform" rating and a $14.00 target price on the stock. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus lowered their price target on Elanco Animal Health from $20.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELAN. Geode Capital Management LLC increased its position in shares of Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company's stock worth $115,623,000 after acquiring an additional 65,303 shares during the last quarter. Atom Investors LP increased its holdings in Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company's stock worth $5,081,000 after purchasing an additional 261,559 shares during the last quarter. Davidson Kempner Capital Management LP acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at approximately $839,000. Wellington Management Group LLP boosted its stake in shares of Elanco Animal Health by 19.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company's stock valued at $58,875,000 after buying an additional 646,522 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Elanco Animal Health by 14.0% during the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock worth $5,349,000 after buying an additional 45,795 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Down 0.7 %

Elanco Animal Health stock traded down $0.08 during trading on Friday, reaching $11.47. The company had a trading volume of 5,032,792 shares, compared to its average volume of 4,728,282. Elanco Animal Health has a 12-month low of $11.11 and a 12-month high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock's 50 day moving average price is $12.69 and its two-hundred day moving average price is $13.54. The firm has a market capitalization of $5.67 billion, a price-to-earnings ratio of 28.68, a PEG ratio of 1.96 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. The company had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business's quarterly revenue was down 3.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.18 EPS. As a group, equities analysts expect that Elanco Animal Health will post 0.92 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.